Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	210 mg Brodalumab	624
Overall Study	STARTED	140 mg Brodalumab	629
Overall Study	STARTED	Ustekinumab	313
Overall Study	STARTED	Placebo	315
Overall Study	COMPLETED	210 mg Brodalumab	608
Overall Study	COMPLETED	140 mg Brodalumab	604
Overall Study	COMPLETED	Ustekinumab	303
Overall Study	COMPLETED	Placebo	301
Overall Study	NOT COMPLETED	210 mg Brodalumab	16
Overall Study	NOT COMPLETED	140 mg Brodalumab	25
Overall Study	NOT COMPLETED	Ustekinumab	10
Overall Study	NOT COMPLETED	Placebo	14

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01708629/flow